Fmr LLC cut its stake in Prothena Co. PLC (NASDAQ:PRTA) by 2.6% in the 4th quarter, HoldingsChannel reports. The fund owned 4,910,430 shares of the biotechnology company’s stock after selling 131,934 shares during the period. Fmr LLC owned 0.12% of Prothena worth $50,577,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in Prothena by 4.3% during the third quarter. BlackRock Inc. now owns 3,311,388 shares of the biotechnology company’s stock worth $43,313,000 after buying an additional 137,301 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Prothena by 1,145.1% during the third quarter. JPMorgan Chase & Co. now owns 101,599 shares of the biotechnology company’s stock worth $1,329,000 after buying an additional 93,439 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Prothena by 2.2% during the third quarter. Teachers Advisors LLC now owns 100,290 shares of the biotechnology company’s stock worth $1,312,000 after buying an additional 2,157 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Prothena by 76.6% during the third quarter. Dimensional Fund Advisors LP now owns 944,666 shares of the biotechnology company’s stock worth $12,356,000 after buying an additional 409,606 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Prothena by 7,725.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 19,955 shares of the biotechnology company’s stock worth $206,000 after buying an additional 19,700 shares in the last quarter.
Shares of NASDAQ:PRTA opened at $10.93 on Wednesday. The company has a market cap of $435.67 million, a P/E ratio of -3.03 and a beta of 2.53. Prothena Co. PLC has a 1-year low of $8.63 and a 1-year high of $38.81.
Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.04). The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.28 million. Prothena had a negative return on equity of 38.98% and a negative net margin of 16,297.91%. On average, equities research analysts predict that Prothena Co. PLC will post -2.44 EPS for the current fiscal year.
A number of brokerages recently weighed in on PRTA. BidaskClub cut shares of Prothena from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald began coverage on shares of Prothena in a report on Monday, March 4th. They set an “overweight” rating and a $13.77 target price for the company. Finally, Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Wednesday, February 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $31.47.
Prothena Company Profile
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Featured Article: Diluted Earnings Per Share
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.